Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Takeover who wrote (6093)	8/5/1999 2:04:00 AM
From: john	Read Replies (1) \| Respond to of 150070

Genelink Inc, (OTCBB: GNLK) Broker Fact Sheet Summary: The concept of mapping the 100,000 known genes in the human body was brought to light with the human genome project. To date researchers have identified 4,500 known inherited genetic diseases. Genelink Inc. (OTCBB: GNLK) will allow families to create a genetic medical history for future generations. Genelink Inc. is the World's First Family Centered DNA Bank and Hereditary Genetic Information Center (Web-Site www.bankdna.com). Genelink Inc. has a do-it-yourself, non-invasive DNA Collection kit. The retail price is $250 that includes 25 years of storage. Patents are pending in the United States, Europe, Japan, and China. Genelink Inc. has a long-term contract with the University of Texas Health and Science Center at Fort Worth, TX (UNTHSC) for the extraction and safe keeping of DNA. UNTHSC is a 105-year-old medical facility and has a national reputation for its state-of–the art DNA/ Identity Laboratory. Genelink Inc. is first targeting the death-care industry because of its reoccurring revenues. In 1998 in the United States alone, 2.8 million casketed burials occurred and 35% of families turning to cremation. DNA collection at death is the last chance for a family to create a genetic history. Genetic scientists need at least three generations to get an adequate over view of families genetic history. This gives Genelink Inc, the reoccurring business to carry us into the new millenium. Investment Highlights: * The Death-Care Industry is looking for new and innovative lead procurement programs. * The emphasis within the death-care industry is on pre-need sales and Genelink Inc. is a direct link to the growing market with its referral program. In the United States it is estimated that between 6,000 and 8,000 pre-need sales representatives are marketing to the general public and Genelink Inc. provides this army of specialized sales people with the perfect post-funeral door opener. * Financing our product: Genelink Inc. has the ability to finance its own sale of products. This will allow Genelink Inc. to serve every family and grow more market share. The insurance industry being a multi-billion dollar business is one of the main funding vehicles for pre-need sales in the funeral and cemetery industry. * The ability for growth in a wide variety of markets: The storage of DNA can take many different forms. Genelink Inc. is doing market research outside of the death-care industry for future growth potential. * Experienced Leadership: Genelink Inc. has a well-defined management infrastructure to lead our worldwide thrust in sales and marketing. Growth Strategy: Future Markets: Expanding the death-care market globally, DNA identification programs: CHIPS- child abductions and paternity issues (who is the father), the storage of cord-blood, pharmaceutical industry, managed care providers, clinical research organizations, and senior market. Death-Care Industry Sales Overview: The basic strategy of Genelink Inc. in capturing the Death-care market is to reach the individual funeral homes and cemetery locations, whether corporate-owned or independently operated, through our own servicing representatives. Our marking representatives will work hand in hand with the funeral home/cemetery staff to educate, train, service, and sell the benefit of Genelink Inc. Conclusion: Genelink Inc. is a service based company whose value goes well beyond the safe confidential collection and storage of the individual Genome through the non-invasive collection of DNA. Medical symposiums and publications have made it clear to us that knowing your family's medical history may save your life. A recent study by the Utah Health Science Center reports that 75% of all major diseases, which are diagnosed, are made as the result of having a family's medical history. Today, Genelink preserves a family's medical history for generations in the medical language of tomorrow! The explosion of new medical information being generated in the field of human molecular genetics will enhance the practice of medicine and alter the health care industry significantly over the course of the next 25 years. Genelink does not claim to offer the answers or define the process of care for individuals seeking medical solutions. It does hold, on behalf of its clients, the key to a generation genetic history. Genelink and the Death-Care Industry have a great deal in common with the market place – both are selling future value of services today.